StockData
Longeveron Inc. logo

Longeveron Inc. (LGVN) stock

LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.92−0.19 (-9.00%)

Close on Nov 18, 2026Market cap $61.21MP/E –Yield –

Longeveron r&d expenses

Research and development expenses are spending on new products and technology.

Longeveron's R&D Expenses for the twelve months ending Jun 30, 2026 was $12.09M, up 25.1% year over year. For fiscal 2025 it was $12.04M, up 48.0% from the year before. The highest annual figure on record is $12.04M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$12.04M+48.0%
FY2024Dec 31, 2024$8.14M-10.2%
FY2023Dec 31, 2023$9.07M-3.2%
FY2022Dec 31, 2022$9.37M+32.1%
FY2021Dec 31, 2021$7.09M+165.2%
FY2020Dec 31, 2020$2.67M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.19M+8.1%
Q1 FY2026Mar 31, 2026$2.32M-7.8%
Q4 FY2025Dec 31, 2025$2.72M+36.8%
Q3 FY2025Sep 30, 2025$3.85M+74.6%
Q2 FY2025Jun 30, 2025$2.95M+71.5%
Q1 FY2025Mar 31, 2025$2.52M+13.3%
Q4 FY2024Dec 31, 2024$1.99M-7.7%
Q3 FY2024Sep 30, 2024$2.21M+19.7%
Q2 FY2024Jun 30, 2024$1.72M-24.7%
Q1 FY2024Mar 31, 2024$2.22M-20.2%
Q4 FY2023Dec 31, 2023$2.16M+25.3%
Q3 FY2023Sep 30, 2023$1.84M+42.6%
Q2 FY2023Jun 30, 2023$2.29M+32.0%
Q1 FY2023Mar 31, 2023$2.78M+35.7%
Q2 FY2022Jun 30, 2022$1.72M-12.2%
Q1 FY2022Mar 31, 2022$1.29M-4.3%
Q4 FY2021Dec 31, 2021$1.73M+50.6%
Q3 FY2021Sep 30, 2021$2.05M+250.1%
Q2 FY2021Jun 30, 2021$1.96M+205.3%
Q1 FY2021Mar 31, 2021$1.35M+367.1%
Q4 FY2020Dec 31, 2020$1.15M–
Q3 FY2020Sep 30, 2020$585.00K–
Q2 FY2020Jun 30, 2020$642.00K–
Q1 FY2020Mar 31, 2020$289.00K–

More Longeveron figures

See a number that looks wrong?